^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Elyxyb (celecoxib)

i
Other names: DFN15, DFN-15, DFN-15A, DFN-15B
Company:
Collegium Pharma, Dr. Reddy’s, Sorrento
Drug class:
COX2 inhibitor
1m
RECON: Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (clinicaltrials.gov)
P2, N=39, Not yet recruiting, Emory University | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
Trial completion date • Trial primary completion date
|
Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Elyxyb (celecoxib) • celecoxib oral
3ms
New P2 trial
|
Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Elyxyb (celecoxib) • celecoxib oral
5ms
Enrollment open
|
erlotinib • methotrexate • Elyxyb (celecoxib) • celecoxib oral
5ms
Trial initiation date
|
erlotinib • methotrexate • Elyxyb (celecoxib) • celecoxib oral
6ms
New P2 trial
|
erlotinib • methotrexate • Elyxyb (celecoxib) • celecoxib oral